BACKGROUND: There is no clear consensus between pediatric and adult providers about the treatment of adolescents and young adults (AYAs) with Hodgkin lymphoma (HL). METHODS: Failure-free survival (FFS) and overall survival (OS) were compared between 114 patients ages 17 to 21 years with HL who were treated on the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Intergroup adult E2496 study and 391 similarly patients ages 17 to 21 years with HL who were treated on the pediatric Children's Oncology Group (COG) AHOD0031 study. RESULTS: Comparing AYAs from the COG and E2496 studies, there were no significant differences in extralymphatic disease, anemia, or hypoalbuminemia. More AYAs in the E2496 trial had stage III and IV disease (63% vs 29%; P < .001) and B symptoms (63% vs 27%; P < .001), and fewer had bulk disease (33% vs 77%; P < .001). More AYAs on the COG trial received radiotherapy (76% vs 66%; P 5 .03), although in smaller doses. E2496 AYA The 5-year FFS and OS rates were 68% and 89%, respectively in the E2496 AYAs and 81% and 97%, respectively, in the COG AYAs, indicating a statistically superior compared in the COG AYAs (P 5 .001). In stratified multivariable analyses, E2496 AYAs had worse FFS than COG AYAs in all strata except patients who had stage I and II HL without anemia. Propensity score analysis (based on stage, anemia, and bulk disease) confirmed inferior FFS for E2496 AYAs compared with COG AYAs (P 5 .004). On the E2496 study, FFS was significantly divergent across age groups (P 5 .005), with inferior outcomes for those ages 17 to 21 years versus 22-44 years. There was no difference across age on the COG study. CONCLUSIONS: Younger AYA patients with HL appear to have better outcomes when treated on a pediatric trial than patients of similar age on an adult trial. Prospective studies examining these differences are warranted. Cancer 2018;124:136-44.
INTRODUCTION
The National Cancer Institute (NCI) recognizes adolescents and young adults (AYAs) (ages 15-39 years at diagnosis) with cancer as a high-priority population for research. 1 Advances in cure rates and participation in oncology clinical trials lag in the AYA age group compared with younger children and older adults. 2, 3 These trends apply to Hodgkin lymphoma (HL), the most common malignancy in this age group.
Although HL is highly curable, there are debates regarding the optimal treatment regimen based on stage, bulk, and interim metabolic response. An unexplored component of treatment approach is the potential interaction between age at diagnosis and regimen. In particular, the majority of patients with HL are in the AYA age range, and there have been various guidelines for management without a clear consensus. In the 18 F-fluorodeoxyglucose-positron emission tomography pre-response-adapted era, adult oncology providers have often treated patients who have newly diagnosed HL using 4 to 6 cycles of combined doxorubicin (Adriamycin), bleomycin, vinblastine, and dacarbazine (ABVD), with radiation recommended for patients who have bulk disease at presentation or in those who do not respond sufficiently to initial chemotherapy. 4 The pediatric approach is based on the Children's Oncology Group (COG) chemotherapy backbone, combined doxorubicin (Adriamycin), bleomycin, vincristine, and etoposide plus prednisone and cyclophosphamide (ABVE-PC), with radiation decisions based on a combination of presenting features as well as response after 2 cycles of chemotherapy. [5] [6] [7] [8] Further distinguishing pediatric and adult management, the pediatric standard of care for radiation uses 21-gray (Gy) involved-field radiotherapy (IFRT) versus 36 Gy in adult regimens.
Prior registry data indicated that AYA patients who had HL treated with ABVD had outcomes that were to those of their older counterparts. 9 However, NCI Surveillance, Epidemiology, and End Results data suggest that advances in HL survival among AYAs may be less robust compared with that in both older and younger populations. 3 Understanding the optimal treatment approach and balancing both survival rates and exposures are particularly important for AYA patients with HL, in part because many years of their lives will be impacted by therapy-related morbidities, such as the risk of a second cancer because of radiation exposure at a young age. 10 This, in turn, can ultimately impact survivors' lifelong health-related quality of life and economic productivity. 11, 12 We sought to examine AYA patients between ages 17 and 21 years (the age group of those typically eligible for both pediatric-based and adult-based HL clinical trials) who were treated on 2 recent, randomized adult and pediatric North American clinical trials in newly diagnosed HL, namely, the intergroup trial Eastern Cooperative Oncology Group-American College of Radiology Imaging Network (ECOG-ACRIN) adult E2496 trial and the COG pediatric AHOD0031 trial. 5, 13 Our objective was to compare both exposures and outcomes among different age cohorts within the E2496 study and across the 2 studies.
MATERIALS AND METHODS
All patients provided informed consent according to federal and institutional guidelines and in accordance with the Declaration of Helsinki. The NCI-approved phase 3 clinical trials included in this analysis (AHOD0031 and E2496) were conducted using IRB-approved protocols.
Eligibility and Treatment

E2496
Eligibility for E2496 included patients who had classic HL with previously untreated, advanced-stage (III/IV) disease or local disease with bulky mediastinum. 13 Bulk disease was defined as a mass over one-third of the maximum intrathoracic dimension on a standing posterioranterior chest x-ray (peripheral bulk was not included in the definition). Histology was determined using central review when available or local review. Between April 1999 and June 2006, 854 patients were enrolled, and 794 were deemed eligible. Of the eligible patients, 114 were ages 17 to 21 years, 529 were ages 22 to 44 years, and 150 were aged 45 years.
Eligible patients were randomized to receive either ABVD or Stanford V (doxorubicin [Adriamycin], vinblastine, nitrogen mustard, etoposide, vincristine, bleomycin, and prednisone). 13 Patients received 6 or 8 cycles (28-day cycles) of ABVD, depending on response by computed tomography (CT) scan. Patients received Stanford V chemotherapy for 12 weeks. Radiation therapy (RT) was received by all patients who had bulky mediastinal adenopathy and was scheduled to begin 2 weeks after the completion of chemotherapy. An RT dose of 36 Gy was delivered to mediastinal, bilateral hilar, and bilateral supraclavicular areas. For patients who received Stanford V, 36-Gy RT was delivered to any pretreatment site measuring >5 cm and for macroscopic splenic disease, as determined by CT scan.
AHOD0031
Eligible patients for AHOD0031 included patients aged <22 years with newly diagnosed, biopsy-proven classic HL; Ann Arbor stages IB, IA extranodal (IAE), IIB, IIAE, IIIA, and IVA with or without bulk disease; and stage IA or IIA with bulk disease. 5 Bulk disease was defined by a mediastinal mass with a diameter greater than one-third of the greatest thoracic dimension on an upright posterior-anterior chest x-ray or extramediastinal lymph node aggregate >6 cm in the longest transverse dimension on an axial CT scan. Between September 2002 and July 2009, 1734 patients were enrolled, and 1712 were deemed eligible. Of those eligible patients, 391 were between ages 17 and 21 years.
All patients received two 21-day cycles of ABVE-PC chemotherapy followed by a CT scan response evaluation. Rapid early responders (RERs), defined as those patients who had a complete response (CR) or a very good response after 2 cycles of chemotherapy by CT scan, received 2 additional ABVE-PC cycles followed by a CR evaluation. RERs who had a CR were randomly assigned to undergo IFRT or observation; RERs who had less than a CR were nonrandomly assigned to receive IFRT. Slow early responders (SERs) were randomly assigned to receive or not receive 2 cycles of dexamethasone, etoposide, cisplatin, and cytarabine (DECA) followed by 2 cycles of ABVE-PC. All SERs were assigned to receive IFRT. All chemotherapy cycles were delivered with granulocytecolony-stimulating factor support. Patients who underwent IFRT received 21 Gy, which was delivered 4 weeks after the completion of chemotherapy to areas of disease that were involved at the time of presentation. Gross tumor volume included any lymph nodes greater than 1.5 cm in a single axis on a CT scan. The clinical target volume included the anatomic compartment containing involved lymph nodes. The planning target volume was determined by the addition of a 1.0-cm margin around the clinical target volume to account for patient motion and set-up variability, with allowable modification at the discretion of the treating radiation oncologist to avoid healthy tissue. Among the patients who were assigned to receive IFRT, those who had pulmonary metastases received 10.5 Gy of whole-lung radiation, regardless of resolution of pulmonary lesions, and those with liver metastases received 15 Gy to the entire liver.
Statistical Analysis
We compared baseline demographics, clinical features, and planned treatment of 114 AYA patients with newly diagnosed HL between ages 17 and 21 years who were treated on ECOG-ACRIN study E2496 versus 391 similar patients (AYAs with newly diagnosed HL between ages 17 and 21 years) who were treated on COG study AHOD0031. Chi-square tests or Fisher exact tests were used to analyze for categorical variables, and t tests and Wilcoxon rank-sum tests were for continuous or ordinal variables. Unstratified and stratified log-rank tests, as well as propensity score analyses, were used to compare differences in patient outcomes (failure-free survival [FFS] and overall survival [OS] ). The initial propensity score was calculated as the predicted probability from a logistic regression model with cohort (ECOG-ACRIN E2496 vs COG AHOD0031) as the dependent variable and stage, anemia, and bulk disease as independent variables. These independent variables were chosen from the International Prognostic Score.
14 Survival was then compared between groups using a stratified log-rank test, with quintiles of the propensity score as the stratification factor. The robustness of the results was confirmed using Cox regression with the propensity score as a covariate. A second propensity score was calculated that also incorporated age, sex, B symptoms, and albumin levels. C-statistics for the 2 propensity score models are reported.
In addition, we examined characteristics and outcomes of the 114 AYA patients with newly diagnosed HL ages 17 to 21 years who were treated on the E2496 trial and compared the FFS and OS rates with those of patients aged >21 years on the E2496 trial using log-rank tests stratified according to the extent of disease (stage), treatment regimen (ABVD vs Stanford V), number of risk factors (0-2 vs 3-7 risk factors). 15 Likewise, we examined characteristics and outcomes of the 391 AYA patients with newly diagnosed HL ages 17 to 21 years who were treated on the COG AHOD0031 trial and compared the FFS and OS rates with those from patients aged <17 years on the COG AHOD0031 trial. Table 1 depicts the demographic and presenting features of the AYA patients (ages 17-21 years) who were treated on the E2496 and AHOD0031 trials. There were no statistically significant differences in sex or race/ethnicity between the patients in this age group in the 2 studies. AYAs on the AHOD0031 study had a mean age at enrollment that was younger than those on the E2496 study (18.2 vs 20.1 years, respectively; P < .001). In terms of presenting features, there were no significant differences in histology distribution, extralymphatic disease, anemia, or albumin levels <4 g/dL. A larger proportion of AYAs on the ECOG-ACRIN trial had stage III and IV disease (63% vs 29%; P < .001). A significantly larger proportion of ECOG-ACRIN AYAs had B symptoms (63% vs 27%; P < .001), whereas a significantly smaller proportion of E2496 AYAs had bulky mediastinal disease at presentation (33% vs 77%: P < .001). However, these patients received no corticosteroids or etoposide. Both E2496 patients who received Stanford V and AHOD0031 patients received etoposide, although patients on the AHOD0031 trial received more exposure. SERs in the AHOD0031 study who were randomized to receive DECA chemotherapy (N 5 36 AYAs) were also exposed to cytarabine and cisplatin, although in relatively low cumulative exposures. A greater proportion of COG AYAs received RT (76.2% vs 65.8%), although in lower doses, (21 vs 36 Gy).
RESULTS
Presenting Features of AYA Patients on ECOG-ACRIN E2496 and COG AHOD0031
Outcomes of E2496 AYAs Versus COG AHOD0031 AYAs
For survival comparison across studies, COG AHOD0031 AYAs had statistically superior FFS compared with E2496 AYAs (P 5 .001) (see Fig. 1 ). More COG AHOD0031 AYAs received RT (76% vs 66%; P 5 .03), although in smaller doses (21 vs 36 Gy). In each group, 3 AYAs developed a second cancer. In survival analyses stratified by stage and anemia, E2496 AYAs had worse FFS compared with COG AHOD0031 AYAs in all strata except among the subgroup of patients who had stage I/II disease without anemia (data not shown). Furthermore, propensity score analysis matched on stage, anemia, and bulk disease (C-statistic 5 0.75) confirmed the inferior FFS for E2496 AYAs compared with COG AHOD0031 AYAs (P 5 .004). Moreover, the AYA survival disparity across studies persisted after additional covariates were incorporated into the propensity score (ie, age, sex, B symptoms, and hypoalbuminemia, with a C-statistic of 0.90 (P 5 .026) (Supporting Tables 1 and 2 ; see online supporting information).
E2496 AYA Outcomes Versus Older Patients From E2496
In E2496, the 5-year FFS and OS rates for AYAs between ages 17 and 21 years were 68% and 89%, respectively. There were significantly divergent outcomes in FFS and OS by patient age (see Table 3 ). There was no difference in FFS between AYAs who received ABVD versus those who received Stanford V (P 5 .66). However, FFS was differed significantly across age groups in E2496 (P 5 .005) (see Fig. 1A,C) . This difference was driven by older patients (aged 60 years) and also suggested that AYAs may have inferior outcomes compared with patients who are diagnosed between ages 22 and 44 years. It is noteworthy that AYA FFS outcomes on E2496 appeared more similar to the outcomes observed among patients ages 45 to 59 years.
COG AHOD0031 AYA Outcomes Versus Younger Patients From AHOD0031
The 5-year FFS and OS for AYAs on the COG AHOD0031 study were 81% and 97%, respectively (see Figs. 1B and 2D) . In contrast to the E2496 study, there were no statistical differences in either FFS or OS between patients ages 17 to 21 years and those younger than 17 years treated on the COG study (P 5 .11 and P 5 .77, respectively).
DISCUSSION
In 2006, the NCI and Livestrong Foundation published a progress review entitled Closing the Gap: Research and Care Imperatives for Adolescents and Young Adults With Cancer," which recommended a more robust research effort to better understand specific cancer outcomes in AYAs and the factors associated with these outcomes. 1 Responding to that progress review, the current study is the first large retrospective analysis of AYAs with HL who were treated on recent North American clinical trials. AYAs with HL between ages 17 and 21 years who received treatment on E2496 had inferior outcomes compared with older patients (ie, ages 22-44 years) who were treated on the same study and compared with similarly matched AYAs who were treated on the COG AHOD0031 study. In previous retrospective registry analyses, investigators from the British Columbia Cancer Agency did not observe differences between AYAs and older adults who received treatment with ABVD. 9, 16 Reasons for the discrepant results from the British Columbia data versus the current analysis of inferior outcomes in patients ages 17 to 21 years in the E2496 study (compared with both older patients on the same study and COG AYA outcomes) are not clear, although several potential explanations exist. First, methodological variances or clinical and demographic differences may have been factors, including trial design differences; indeed, a greater proportion of patients on the E2496 trial had stage III or IV HL with bulk disease (see Table 1 , footnote). Moreover, the definitions of bulk between the COG and ECOG-ACRIN groups were different (in addition to a mediastinal mass with a greatest dimension greater than one-third of the thoracic diameter on chest x-ray, COG included patients who had an extramediastinal lymph node aggregate >6 cm in the longest transverse dimension on an axial CT scan, whereas ECOG-ACRIN did not). However, analyses controlling for stage at diagnosis, the presence of B symptoms, or bulk disease, as well as other prognostic factors, still reflected these worse outcomes in E2496 AYAs. In addition, although the aforementioned British Columbia Cancer Agency study was a retrospective registry analysis with strength of complete data in a centralized care setting, the current data have the strength of being derived from prospective, randomized, controlled clinical trials. Clinical practices for AYAs receiving treatment in pediatric versus adult centers may influence patient outcomes, such as differences in treatment regimens or in the dose-intensity of treatment plans. General compliance differences among AYA patients treated at pediatric versus adult centers may have played a role. In an analysis of AYAs with acute lymphoblastic leukemia ages 16 to 20 years, investigators indeed observed that AYAs who received treatment on adult clinical trials had outcomes that were inferior to those of AYAs who received treatment on pediatric trials and they hypothesized that adherence and lack of support services contributed in part to poorer outcomes on the adult trials. 17 Psychosocial support and related services are typically more available and comprehensive at pediatric cancer centers in the United States. Furthermore, the COG regimen ABVE-PC is a dose-intense regimen given every 3 weeks. Although it was delivered at lower doses, more COG AYAs received RT. Both in AHOD0031 and in the original study of ABVE-PC, there were minimal treatment delays or dose modifications (personal communication, Debra L. Friedman). 6 By comparison, investigators were given specific directives to dose delay and modify ABVD therapy for modest cytopenias in the E2496 trial (eg, doxorubicin and vinblastine were decreased by 25% for an absolute neutrophil count <1800/mm 3 , and all drugs were held for at least 1 week for an absolute neutrophil count <1200/mm 3 ). Unfortunately, dose delays and modifications were not captured as part of data collection in the E2496 trial. More recent US intergroup studies using the ABVD backbone do not allow for delays or dose reductions for neutropenia, and future comparisons between patients treated on these adult cooperative group studies with patients who receive pediatric regimens may better elucidate differences in the efficacy of chemotherapy backbones.
Disease biology for AYAs compared with their older counterparts could possibly explain these differences. A COG group recently reported the application of a published gene expression profiling 23-gene model developed for adults in 185 pediatric patients from the AHOD0031 trial. The assay failed to predict outcomes, suggesting that distinct biology predicts treatment failure in pediatric patients, 18 although the study did not take into account the different treatment regimens between pediatric and adult providers. .0%-82.2%); whereas, in patients ages 45 to 59 years (N 5 68) the 3-year FFS was 83% (95% CI, 72.0%-90.5%) (for survival curves, see Supporting Fig. 1 ; see online supporting information). 19 It is important to highlight that, in addition to response-adapted therapy, as noted above, ABVD was prescribed in S0816 to be given in full doses and without treatment delay, irrespective of the absolute neutrophil count on the day of treatment, as previously reported. 20, 21 Collectively, when considering the treatment of young patients with HL, it is also imperative to consider therapeutic exposures. HL is associated with high rates of premature mortality because of significant therapy-related morbidities, including cardiac disease, pulmonary disease, and second cancers. Studies examining the late effects of childhood cancer and, more specifically, HL have demonstrated that these late effects and second cancers are related 2 . However, planned RT was more extensive in patients who were randomized to receive Stanford V. Overall, fewer patients received RT in the E2496 study (approximately 66%). Although exposures differed, the absolute number of second cancers reported in each study was the same (n 5 3), although longer follow-up is warranted. Unfortunately, the late cardiac and pulmonary outcomes have not been examined to date in either of these trials.
Our study has several limitations that need to be considered when interpreting these results. This was not a randomized comparison of ECOG-ACRIN and COG treatment approaches in AYAs. Therefore, there were inherent differences in trial designs and patient characteristics between the E2496 and AHOD0031 trials that limit our ability to draw definitive conclusions. The staging evaluation and response criteria were not uniform across studies; and, unfortunately, despite harmonization efforts being undertaken during the last 2 decades (the International Harmonization Project and the Lugano Classification), it is very difficult to compare trials. 22, 23 We recognize that, although we used propensity scores to take these differences into account, this methodology alone cannot guarantee that the 2 cohorts are comparable. Moreover, our ability to examine adherence to the prescribed treatment in each of the trials was limited, in that providers were at their own discretion in determining delays and dose modifications, and documentation of these delays and modifications was not mandated by the trials.
In conclusion, the results of our retrospective analysis of 2 recent phase 3 randomized HL studies demonstrate that younger AYAs (ages 17-21 years) who were treated on the intergroup trial E2496 had outcomes that were inferior to those in older patients who were treated on the same study and in similarly aged patients who were treated on the pediatric COG AHOD0031 trial. These outcomes may result from differences in treatment regimen or dose intensity, treatment compliance, differing patient populations or risk profiles, disease biology, and/ or other factors. Prospective examination of these issues in AYA patients with HL is needed.
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